CDKN2A and malignant peripheral nerve sheath tumor: To study PRC2 loss in both p53- and Cdkn2a-null contexts, we used CRISPR/Cas9 to inactivate Eed or Suz12 in murine MPNST cell lines derived from 2 complementary mouse models of spatially and temporally restricted MPNST (Figure 1A).